The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota

Immune agonist antibodies (IAAs) are promising immunotherapies that target co-stimulatory receptors to induce potent anti-tumor immune responses, particularly when combined with checkpoint inhibitors.

Citation:
Blake SJ, James J, Ryan FJ, Caparros-Martin J, Eden GL, ……. O’Gara F, et al. The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota. Cell Rep Med. 2021;2(12):100464.

Keywords:
Anti-CD137; anti-CD40; cytokine release syndrome; gut microbiota; immune agonist antibody; immunotherapy; liver damage

Abstract:
Immune agonist antibodies (IAAs) are promising immunotherapies that target co-stimulatory receptors to induce potent anti-tumor immune responses, particularly when combined with checkpoint inhibitors.